Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy - A Single Arm Phase I/II Trial
Latest Information Update: 11 Jul 2022
Price :
$35 *
At a glance
- Drugs Nelfinavir (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 04 Jul 2022 Status changed from active, no longer recruiting to discontinued.
- 20 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Jun 2022.
- 20 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2022.